Table 2.

Overall adverse events summary for participants starting at 3 μg or 30 μg of Nexvax2.

Treatment	Nexvax2	Nexvax2	Nexvax2	Nexvax2	Nexvax2	Placebo
Starting dose, μg	30	30	3	3	3
Maintenance dose, μg	300	300	300	300	900
Cohort	1	2	1	2	3	All
Participants, n	2	4	5	6	10	9
Participants with any adverse events	2 (100%)	4 (100%)	3 (60%)	6 (100%)	9 (90%)	9 (100%)
Participants with any drug-related adverse events	2 (100%)	4 (100%)	3 (60%)	6 (100%)	7 (70%)	8 (89%)
Participants with any adverse events graded at least moderate in severity	2 (100%)	3 (75%)	2 (40%)	5 (83%)	6 (60%)	4 (44%)
Participants with any adverse events graded at least moderate in severity and drug-related	1 (50%)	2 (50%)	1 (20%)	4 (67%)	2 (20%)	2 (22%)
Participants who withdrew due to adverse events	1 (50%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (11%)
Participants with any serious adverse events	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (22%)
Adverse events	34	57	16	56	44	46
Adverse events drug-related	21	45	9	41	20	25
Adverse events graded at least moderate in severity	7	5	3	17	12	7
Adverse events graded at least moderate in severity and drug-related	5	2	1	13	2	4
Adverse events leading to withdrawal	1	0	0	0	0	1
Serious adverse events	0	0	0	0	0	2

Data are n (%).